India, Feb. 8 -- Thermo Fisher Scientific has received 510(k) clearance from the US Food & Drug Administration (FDA) for theApplied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel, offering a single clinical testing solution for four of the most common respiratory viruses circulating in flu season.
This real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) and enables detection of co-infection.
Respiratory infections often present with overlapping signs of infection, making it difficult to accurately differentiate between common respiratory viral infections and therefore detect the specific pathogen responsible fo...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.